Business Wire

ADVA boosts PNT resilience with new software release

Share

ADVA (FSE: ADV) today announced the latest software release of its core and edge timing technology, bringing new levels of PNT security and resilience to synchronization networks. The upgraded series of PTP grandmaster clock solutions now enables operators to automatically harness public key infrastructure. Along with enhanced certificate management, this delivers more robust security and removes complexity. ADVA’s core and mid-sized PTP grandmaster devices now also integrate enhanced aPNT+™ technology, providing advanced jamming and spoofing detection as well as mitigation with automatic switchover in the event of cyberattacks. The software replaces costly hardware devices previously used for PNT protection and achieves enhanced DHS Level 4 Resiliency in PNT self-survivability, the highest in the industry. What’s more, the new software release supports 100Mbit/s over fiber for interconnectivity with optical timing channels from third-part vendors as well as support for PTP profiles for a wide range of industries.

“Today’s timing networks require greater accuracy than ever before. But mission-critical national networks need improved resilience and security as defined by the latest standards. With our trusted PNT assurance solutions, we’re providing the GNSS protection and cybersecurity that today’s operators need to meet current and future challenges,” said Gil Biran, GM of Oscilloquartz, ADVA. “From phase synchronization in critical national infrastructure to traceable timestamping in financial networks, highly precise and protected timing is key to successful operations. This upgrade sets a new standard for secure synchronization and delivers it to more networks than ever before.”

The new 11.1.1 software release features upgrades to ADVA’s comprehensive range of Oscilloquartz edge timing products, the OSA 5412/22 Series, as well as its core synchronization devices, the OSA 5430/40 Series. The solutions now provide multi-layered security for synchronization infrastructure through improved certification management and PKI. As part of ADVA’s intelligent and scalable assured PNT platform, the ADVA aPNT+, the solutions also feature innovation for detection of spoofing and jamming as well as countermeasures to prevent service disruption. With PTP capabilities for new verticals, including the PTP broadcast profiles (SMPTE ST-2059-2/AES67), the new release will bring precise, reliable synchronization to many new customers.

The new release follows the four layers of augmented protection as defined in the DHS Resilient PNT Conformance Framework (IEEE P1952 Resilient PNT UE working group). These are: antenna level with a new anti-jamming antenna; GNSS receiver level with single and multi-band options; device level with state-of-the-art anti-jamming and spoofing technology; and network level with sophisticated anti-jamming and anti-spoofing technology based on our Ensemble Controller with Sync Director management suite. Additionally, the device and network levels integrate multi-source backup for diversity and multi-level fault-tolerant mitigation for trusted PNT assurance protection, prevention and recovery.

“In a lot of industries and government networks, failure of network synchronization is no longer an option. It could have devastating consequences for a business’s future or even put lives at risk. That’s why more and more customers are deploying our portfolio of the most advanced and comprehensive aPNT+ timing technology. As well as ensuring nanosecond accuracy, our enhanced series of PTP grandmasters now provide the most robust defense against cyberattacks,” commented Nir Laufer, VP of product line management at Oscilloquartz, ADVA. “This release extends many of our most powerful features beyond telecom. It opens the door for government, defense, broadcasters, data centers, smart grids and more to take advantage of technologies like our multi-band receivers and AI-power GNSS protection.”

Further information is available in these slides: https://adva.li/apnt-security-enhancements-slides.

About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.

About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.

Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com

For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes7.12.2022 10:39:00 CET | Press release

The DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with empagliflozin compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes.1 When empagliflozin was added to other baseline treatments (diet, exercise, metformin and/or insulin) HbA1c was reduced by 0.84% compared with placebo at week 26 (95% CI –1.50 to –0.19; P=0.012).1 The results were presented today at the International Diabetes Federation (IDF) World Diabetes congress 20221, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005405/en/ The DINAMO (DIabetes study of liNAgliptin and eMpagliflozin in children and adOlescents) trial included youth aged 10-17 years with type 2 diabetes and HbA1c ≥6.5% and ≤10.5%. Participants were randomly assigned treatmen

Opening Ceremony Held for NTHU’s Center for Dissection Education and Research7.12.2022 10:00:00 CET | Press release

The opening ceremony for National Tsing Hua University (NTHU) in Taiwan’s Center for Dissection Education and Research, which cost over NT$100 million, was recently held. The ceremony included a memorial service for the cadaver donors. As an expression of gratitude, the first batch of students in the Post-baccalaureate Program in Medicine also offered Chinese bellflowers to the donors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005054/en/ Students of the Post-baccalaureate Program in Medicine at NTHU offering Chinese bellflowers to those who have donated their cadavers to the program. (Photo: National Tsing Hua University) At the ceremony, former NTHU president Hocheng Hong signed the first donation agreement, which indicates that the donor has unconditionally pledged his body for education and research after death, for the purposes of advancing medical science. Current NTHU president W. John Kao thanked Hocheng fo

BIOCORP Obtains 510(k) FDA Clearance for Mallya ®7.12.2022 07:30:00 CET | Press release

Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, announced today that they have received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: "This approval is a major achievement for BIOCORP and all of our employees who have been heavily involved in this regulatory process. This approval marks a historic achievement for BIOCORP as it allows the commercial launch of our Mallya device in the United States and illustrates BIOCORP's ability to meet the highest regulatory requirements. This news has been eagerly awaited by all our industry partners to commercialize Mallya in the world's largest diabetes market and we are delighted that U.S. patients will soon be able to benefit from Mallya's services. This regulatory milestone will have a positive

Delta-Fly Pharma, Inc. is granted Orphan Drug Designation by US Food and Drug Administration for DFP-109177.12.2022 07:11:00 CET | Press release

Delta-Fly Pharma, Inc. announces that DFP-10917, a leading pipeline of the company, is granted Orphan Drug Designation (ODD) by US Food and Drug Administration (FDA) for the treatment of Acute Myeloid Leukemia (AML). Be given to ODD, Delta-Fly Pharma, Inc. can be entitled to seven extra years of marketing exclusivity and receive some benefits such as R&D rebate by getting approval. DFP-10917 is an anti-cancer agent in development for the treatment of patients with Refractory/Relapsed AML. A Phase 3 clinical study has been underway at MD Anderson Cancer Center in Texas and other major sites of Hematologic Cancer Treatment in USA. The company expects to complete the patients’ enrollment plan soon. Delta-Fly Pharma, Inc. focuses not only on cancer itself but on the whole conditions of cancer patients, and aims to deliver medicines that are recommendable for cancer patients and their families. Company profile Company name Delta-Fly Pharma, Inc. [Tokyo:4598] Capital 3352 million Japanese Ye

SLB Announces Pricing of Debt Tender Offer6.12.2022 22:05:00 CET | Press release

SLB (NYSE: SLB) today announced the consideration payable in connection with the previously announced offer (the “Offer”) by Schlumberger Holdings Corporation, an indirect wholly-owned subsidiary of SLB (“SHC”), to purchase for cash up to a certain amount of the notes listed in the table below (the “Notes”), pursuant to the terms and subject to the conditions set forth in the offer to purchase, dated November 21, 2022 (as may be amended or supplemented from time to time, the “Offer to Purchase”). Capitalized terms used but not defined in this press release have the meanings given to them in the Offer to Purchase. Title of Security CUSIP Numbers Acceptance Priority Level(1) Principal Amount Outstanding Principal Amount to be Purchased Early Tender Premium(1) Reference Security Bloomberg Reference Page Reference Yield Fixed Spread (basis points) Total Consideration (1)(2) 3.750% Senior Notes due 2024 806851AJ0 (144A) / U8066LAG9 (Reg S) 1 $750,000,000 $394,869,000 $30 2.500% U.S. Treasur

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom